OBJECTIVES: In 2010, the European Medicines Agency (EMA) with Health Technology Assessment bodies (HTAbs), established parallel scientific advice (SA) that allows manufacturers to receive formal, consolidated feedback from the European Union (EU) regulators and HTAbs on their development plans for new medicines. This study aimed to assess the impact of integrated SA (ISA) on clinical development and health technology assessment (HTA) of new medicines in Europe. METHODS: A systematic search was performed for publications that analysed the impact of ISA. Manufacturers' compliance with the advice provided by EMA and HTAbs, the outcome of marketing authorisation (MA) and reimbursement were analysed. 'Impact' was defined as the influence on the manufacturers' clinical development programme and the outcome of MA and HTA appraisal. RESULTS: The systematic search identified twelve studies; six studies explored the impact of SA on evidence generation programmes, authored by EMA or HTAb representatives. The publications analysed previous SA advice meetings and explored questions asked by the manufacturers and level of compliance between stakeholders in a qualitative and quantitative manner. There has been a marked increase in integrated scientific engagement in recent years. Manufacturers most frequently complied with EMA advice, followed by compliance with at least one HTAb. SA was frequently followed for study design and least followed was comparator advice (57%) where frequently the HTAb and EMA were not aligned. For parallel SA performed between 2010-2015, the products which gained MA, also gained positive reimbursement decisions from most of the HTAbs. For parallel and HTA-only SA, the majority of remaining products continued in clinical development and other products failed development. CONCLUSIONS: ISA offers a valuable dialogue opportunity for stakeholders from different perspectives. This analysis demonstrates that SA may increase manufacturers' chance to obtain regulatory and reimbursement recommendation. Research from other stakeholders (e.g. patient representatives) will provide further understanding of the impact of SA.
Several novel chiral organocatalysts derived from thiazolidines containing amide and thioureia functionalities were synthesized in good yields. These organocatalysts were tested in the asymmetric aldol reaction of acetone with p-nitrobenzaldehyde. Reaction parameters such as reaction time, catalyst loading and solvent were optimized. Products with conversions up to 84% and enantiomeric ratios (er) up to 84.5:15.5 (R:S) were obtained. The effect of several chiral and non-chiral additives on the reactivity and selectivity of the reaction was also evaluated. The reaction was extended to other aromatic aldehydes with the best organocatalyst and when p-bromobenzaldehyde was used, an er of 94.5:5.5 (R:S) was obtained.
from the (mandated) Systemic Anti-Cancer Therapy (SACT) dataset, and 12 utilised the Blueteq database, owned by Public Health England and NHS England, respectively. The MAAs for HSTs have clearly defined funding and exit strategies, stating that NHS funding would cease for all patients if NICE do not recommend the treatment at the end of the MAA, including those already receiving treatment. In contrast, the 16 MAAs within the CDF lacked stated treatment withdrawal protocols upon negative opinion, focussing more on areas of uncertainty. CONCLUSIONS: MAAs for HST have longer duration with less clearly defined goals than those within the CDF. However, the arrangements for data collection and storage, funding, and exit strategy receive greater emphasis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.